International Neuroendocrine Cancer Alliance的动态

September is #ThyroidCancerAwarenessMonth! According to the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute (NCI), an estimated 44,020 people living in the United States will be diagnosed with thyroid cancer in 2024. Help treat your patients who suffer from thyroid cancer with our CoolSeal? Reveal device—an open sealer, divider, and dissector designed to help maximize visibility in tight spaces with <1 mm of average thermal spread. Learn more: https://bit.ly/45EOMWY #Hologic #Healthcare #ThyroidCancer #VesselSealing

Listen to our podcast with Dr. Otis Brawley, Bloomberg Distinguished Professor of Oncology and Epidemiology, speaking about cancer research, the importance of prevention and accessible, high-quality care, including appropriate screening, diagnostics and treatment. Tune in. #TheHealthPulse https://2.sas.com/6041chEj5

EVENT: USC Cancer Epidemiology Seminar Series with Alexandra White, PhD. Talk Summary:?Air pollution is an established carcinogen based on evidence for lung cancer, but much less is known about other cancer types. This talk will describe new findings on outdoor air pollutants and the risk of breast, uterine and ovarian cancer in women using data from large prospective U.S. cohort studies and discuss important future directions. ??? Wednesday,?October 16?| 10 AM ? Learn more: https://lnkd.in/gaDYCUES

Historically, our public health message has been focused on increasing activity levels for all individuals. But at least 50% of U.S. adults already engage in enough aerobic physical activity to be at low risk for premature mortality. The 50% figure with some reasonable level of physical activity is consistent with recent physical activity national surveys. Should we then be concerned that adults can become less active as they age and hence become at an increased risk for chronic conditions and premature mortality? If so, public health messaging should place more emphasis on the maintenance of healthy activity levels across the adult life course. And potentially shape the social norm for a more active lifestyle. Great insight from Chuck Matthews at National Cancer Institute (NCI) that I had the pleasure to be part of along with David Berrigan. NCI Cancer Epidemiology and Genetics Champalimaud Foundation https://lnkd.in/dhzwQPMG

SEER in the news: Generation X showing higher rates of new cancer diagnoses https://lnkd.in/etCeUa7c In a recent study published in JAMA Network Open, researchers from NCI Cancer Epidemiology and Genetics used de-identified cancer data from the Surveillance, Epidemiology, and End Results (SEER) Program to study if rates of new cancer cases are increasing or decreasing across different generations in the US. Men and women from Generation X had higher rates of new cancer cases compared to their parents’ generations. Read the article to see which cancer types increased the most: https://lnkd.in/eyeNKa7S #CancerResearch #PoweredBySEER #SEERSupportsCancerResearch #CancerStatistics #CancerData #CancerTrends

Renal cell carcinoma (RCC) is a common cancer, with an estimated 434 840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. This review summarizes the epidemiology, clinical presentation, pathophysiology, and management of RCC. https://ja.ma/4ebq5Go

I can't believe it has been 10-years! We launched this webinar as next generation sequencing technologies were beginning to more broadly be used in cancer epidemiology studies. I am excited to hear more about the past, present and future of these types of studies!

RENAL CELL CARCINOMA (RCC) Overview of Molecular Biology and Therapeutic Targets in Renal Cell Carcinoma (#RCC) RCC is a common malignancy, with an estimated 434?840 incident cases worldwide in 2022. In the US, it is the sixth most common cancer among males and ninth among females. Peak RCC incidence occurs between the ages of 60 and 70 years and is more common in males than females (a ratio of approximately 3:2). Multiple risk factors associated with it have been identified, and most risk factors have a dose-response relationship with increasing exposure, including systolic hypertension, diastolic hypertension, smoking, kidney disease, and environmental exposures such as heavy metals and industrial solvents. More than 16% of cases worldwide are associated with obesity, although patients with obesity are less likely to present with an advanced stage than are patients with normal weight. RCC is also associated with several hereditary cancer syndromes Many patients (37%-61%) are diagnosed with RCC incidentally on an abdominal imaging study such as ultrasound or computed tomographic scan, and 70% of patients have stage I RCC at diagnosis. Although its incidence has increased approximately 1% per year from 2015 through 2019, the mortality rate of RCC has declined about 2% per year in the US from 2016 through 2020. Patients with a solid renal mass or complex cystic renal mass should be referred to urology. Treatment options for RCC confined to the kidney include surgical resection with partial or radical nephrectomy, ablative techniques (eg, cryoablation, radiofrequency ablation, radiation), or active surveillance for some patients (especially those with renal masses <2 cm). For patients with renal masses less than 4 cm in size (48% of patients), partial nephrectomy can result in a 5-year cancer-specific survival of more than 94%. For advanced or metastatic RCC, combinations of immune checkpoint inhibitors or the combination of immune checkpoint inhibitors with tyrosine kinase inhibitors are associated with tumor response of 42% to 71%, with a median overall survival of 46 to 56 months.

This week I'm working on the outline for a review on follicular lymphoma. While writing the section on epidemiology, I was reminded of a common mix-up in terms that can sometimes occur in medical literature: incidence vs. prevalence. Let’s clarify: ?? Incidence refers to the number of new cases of a disease diagnosed in a specific time period (e.g. 1 year). It is a measure of risk and helps us understand the likelihood of a person developing the disease within that timeframe. ?? Prevalence refers to the total number of cases of a disease in a population at a given time. It provides insights into the overall burden of the disease on society and includes both new and pre-existing cases. Understanding these distinctions is crucial for accurate communication in epidemiological studies and beyond. #medicalcommunication #clinicalresearch #medicalwriting

NOW PUBLISHED in Cancers: study results, which include 5,651 patients in the National Cancer Institute’s Surveillance, Epidemiology and End Results (SEER) Program Registries, support the use of DecisionDx-Melanoma in stage I melanoma to help inform clinical decision-making. Highlights: https://hubs.la/Q02mf4kQ0